Skip to main content

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

Completed · Phase 2 · NCT04658186

Conditions: Early-stage Parkinson's Disease

At a glance

Research payments reported, 2025
$492,689
U.S. investigators named
33
Sites paid
33
Planned or actual enrollment
496

About the trial

Sponsor
UCB Biopharma SRL (with The Parkinson Study Group)
Tested
UCB0599 (drug), Placebo (drug)
Dates
Started 2020-12-30; completion 2024-09-06
Results posted
Yes

The purpose of the study is to assess the safety and tolerability of UCB0599 and to demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of disease progression over 12 and 18 months in participants diagnosed with early-stage Parkinson's Disease.

From ClinicalTrials.gov, last updated 2025-10-31. Full record, eligibility and contacts (opens in a new tab)

Industry funding

UCB SA reported $492,689 in research payments for this study in 2025 (33 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.